Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Wegovy pen delivers a pre-measured dose of semaglutide — a GLP-1 receptor agonist — through a short, fine needle into the fat just beneath the skin. Each injection is once weekly, and the pen itself is designed so that the needle is never visible during use. Wegovy is a prescription-only medicine, meaning a clinical assessment must confirm it is appropriate for you before treatment begins. This page explains exactly what the device does, how to use it safely, and what to expect at each stage of your dose journey, drawn from the NHS's patient guidance on semaglutide and the Wegovy SmPC.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Each Wegovy pen is a single-patient pre-filled injector. Inside the barrel sits a cartridge of liquid semaglutide. When you press the pen against your skin and activate it, a spring mechanism drives the needle forward (you won't see it) and automatically delivers the full pre-set dose before retracting. There is nothing to draw up, no separate needle to attach for routine injections, and no dial to twist to the right number. The device removes most of the steps that people find anxiety-inducing about self-injection.
The pen is disposable. Once a four-week supply of doses is complete, it is spent and should go into a sharps container rather than household rubbish. A new pen begins the next period of treatment. If you want a broader look at the different Wegovy pen formats available, including the newer 7.2 mg single-dose device approved by the MHRA in April 2026, that page covers the distinctions in detail.
The concealed needle is short and fine (typically 4–5 mm) which is why most people report less discomfort than they anticipated. If you're curious about how a Wegovy pen works mechanically, including the spring, cartridge and retraction sequence, that page walks through each stage clearly. The injection deposits semaglutide into the subcutaneous layer, where it is absorbed gradually. That slow absorption is part of why once-weekly dosing works: the drug's long half-life keeps plasma levels stable across seven days.
Three areas are licensed injection sites: the abdomen (avoiding the two-inch zone around the navel), the front of the thigh, and the outer upper arm. Rotating between them (and between spots within each area) reduces the risk of lipohypertrophy, the small lumpy deposits of fat that can form when the same point is used repeatedly. Lumpy tissue absorbs medicine less reliably, so rotation is practical as well as cosmetic.
Before injecting, wipe the chosen spot with an alcohol swab and allow it to dry completely, wet alcohol stings more and marginally affects sterility. Press the pen firmly flat against the skin, activate it, then hold it in place for several seconds after the click. Lifting it too early is the most common cause of incomplete delivery. If you notice a droplet on the skin afterwards, the full dose may not have been absorbed; note it in your injection log and mention it to your prescriber at the next check-in.
A quick checking habit worth building: before every injection, tilt the pen and look through the viewing window. The liquid should be clear and colourless. Any cloudiness, particles, or discolouration means the pen should not be used, contact your prescriber or pharmacist that day. This takes under a minute and catches the rare case of a compromised cartridge. For a fuller account of how semaglutide works inside the body once it's absorbed, this page on the mechanism of semaglutide injections goes deeper into the biology.
Wegovy's dose schedule is a gradual escalation designed to let your body adjust to semaglutide before reaching the maintenance level. Treatment opens at 0.25 mg weekly, this is not the therapeutic dose; it is a settling-in period aimed at reducing the nausea and digestive effects that hit hardest when the medicine is new. Steps move through 0.5 mg, 1.0 mg, 1.7 mg, and then 2.4 mg, with roughly four weeks at each level. If you'd like to understand how Wegovy pens work across the different dose strengths, including what changes between devices at each step, that page covers the full escalation range. The MHRA's approval of a dedicated 7.2 mg pen in April 2026 adds a further optional step for eligible adults, subject to prescriber assessment.
Your prescriber decides when to move up, not the calendar alone. If a particular dose is causing significant side effects, the standard clinical approach is to stay at that level longer rather than push through discomfort. At nume, every repeat order receives a clinical review before dispatch, which is the point at which dose progression is assessed. There are no automatic step-ups.
Side effects during escalation are typically gastrointestinal: nausea, loose stools, or reduced appetite that can tip into genuine discomfort. They tend to be most noticeable in the first week or two at a new dose, then settle. Persistent or severe symptoms (particularly intense stomach pain that moves into the back) need prompt medical attention. The MHRA Yellow Card scheme allows patients to report any suspected side effects directly to the regulator, which helps build the post-market safety picture for newer medicines like Wegovy.
Cost context sits alongside all of this practically. Private Wegovy pricing varies by dose and provider; if you are weighing up what the treatment commitment actually involves financially, this overview of Wegovy costs in the UK sets out what legitimate pricing typically covers and what to watch for.
Missing a single weekly injection does happen. The detail of what to do (whether to inject as soon as you remember or skip to the next scheduled day) depends on how many days have passed, and the right answer is in your Patient Information Leaflet and with your prescriber, not in a general content page. What is consistent across GLP-1 medicines is that doubling up to compensate is not appropriate.
Pen malfunctions are uncommon but not unknown. If the pen clicks without resistance, fails to click at all, or the dose counter does not advance, do not attempt a second injection assuming the first failed. Contact your prescriber or the nume support team to talk through what happened before the next dose. Keeping the original box with the batch number makes any product quality query easier to resolve. Spare replacement needles are worth having if your pen format requires needle changes, though the standard Wegovy autoinjector does not, check your specific device's instructions to confirm.
For people considering whether Wegovy is the right choice overall, or who want to understand how it compares with tirzepatide, the main Wegovy page covers eligibility, evidence and the clinical picture in full. When you are ready to discuss your own situation with a prescriber, starting a free consultation with our team is the next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.